First Sponsor Group Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de First Sponsor Group.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Real Estate croissance des bénéfices	29.5%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	None
Dernière mise à jour	n/a

Mises à jour récentes de la croissance future

Recent updates

First Sponsor Group (SGX:ADN) Seems To Be Using A Lot Of Debt

Oct 21

First Sponsor Group's (SGX:ADN) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Apr 09

Here's Why First Sponsor Group (SGX:ADN) Is Weighed Down By Its Debt Load

Oct 03

These 4 Measures Indicate That First Sponsor Group (SGX:ADN) Is Using Debt Extensively

Jun 03

One First Sponsor Group Limited (SGX:ADN) Analyst Is Reducing Their Forecasts For This Year

Apr 29

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme First Sponsor Group n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

SGX:ADN - Estimations futures des analystes et données financières antérieures (SGD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2024	320	14	-196	-181	N/A
3/31/2024	301	13	-314	-289	N/A
12/31/2023	283	13	-432	-397	N/A
9/30/2023	366	42	-403	-369	N/A
6/30/2023	448	71	-375	-340	N/A
3/31/2023	438	101	-51	-27	N/A
12/31/2022	427	131	273	285	N/A
9/30/2022	488	128	201	210	N/A
6/30/2022	548	124	129	135	N/A
3/31/2022	568	123	-16	-9	N/A
12/31/2021	589	121	-161	-153	N/A
9/30/2021	413	102	-56	-49	N/A
6/30/2021	257	114	161	166	N/A
3/31/2021	236	110	N/A	N/A	N/A
12/31/2020	204	100	153	170	N/A
9/30/2020	314	187	148	182	N/A
6/30/2020	299	180	82	118	N/A
3/31/2020	320	165	N/A	N/A	N/A
12/31/2019	319	164	121	158	N/A
9/30/2019	301	127	0	19	N/A
6/30/2019	310	119	-60	-44	N/A
3/31/2019	275	115	-188	-172	N/A
12/31/2018	277	108	-297	-297	N/A
9/30/2018	326	95	-298	-295	N/A
6/30/2018	337	93	-173	-168	N/A
3/31/2018	349	91	N/A	-5	N/A
12/31/2017	384	88	N/A	37	N/A
9/30/2017	228	119	N/A	254	N/A
6/30/2017	245	116	N/A	200	N/A
3/31/2017	237	115	N/A	108	N/A
12/31/2016	199	113	N/A	107	N/A
9/30/2016	276	72	N/A	35	N/A
6/30/2016	265	70	N/A	11	N/A
3/31/2016	248	69	N/A	51	N/A
12/31/2015	215	67	N/A	-62	N/A
9/30/2015	199	55	N/A	-64	N/A
6/30/2015	182	52	N/A	-58	N/A
3/31/2015	158	42	N/A	-246	N/A
12/31/2014	153	22	N/A	-251	N/A
9/30/2014	77	12	N/A	-174	N/A
6/30/2014	110	16	N/A	-117	N/A
3/31/2014	134	29	N/A	47	N/A
12/31/2013	158	48	N/A	131	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de ADN est supérieure au taux d'épargne ( 2.2% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de ADN devraient croître plus rapidement que le marché SG

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de ADN devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de ADN devraient croître plus rapidement que le marché SG.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de ADN devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ADN devrait être élevé dans 3 ans

First Sponsor Group Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target decreased to S$1.39

Price target decreased to S$1.39

Consensus forecasts updated

Consensus EPS estimates increase to S$0.11

Analysts lower revenue estimates to S$255.3m

Recent updates

First Sponsor Group (SGX:ADN) Seems To Be Using A Lot Of Debt

Upcoming dividend of S$0.011 per share

New minor risk - Earnings quality

Final dividend of S$0.011 announced

First Sponsor Group Limited Announces Retirement of Yee Chia Hsing as the Lead Independent Director and Non-Executive Director

First Sponsor Group's (SGX:ADN) Sluggish Earnings Might Be Just The Beginning Of Its Problems

Full year 2023 earnings released: EPS: S$0.013 (vs S$0.14 in FY 2022)

First Sponsor Group Limited, Annual General Meeting, Apr 25, 2024

High number of new directors

First Sponsor Group Limited Appoints Ms. Low Beng Lan as Independent Non-Executive Director

Non-Executive Chairman exercised options to buy S$944k worth of stock.

Full year 2023 earnings released: EPS: S$0.013 (vs S$0.14 in FY 2022)

First Sponsor Group Limited Proposes Final Cash Dividend for the Year Ended December 31, 2023, Payable on 27 May 2024

New minor risk - Financial data availability

Here's Why First Sponsor Group (SGX:ADN) Is Weighed Down By Its Debt Load

New minor risk - Shareholder dilution

Upcoming dividend of S$0.011 per share at 3.1% yield

New major risk - Financial position

First Sponsor Group Limited Declares First Interim Tax-Exempt Dividend for the Financial Year Ending 31 December 2023, Payable on 2 October 2023

Upcoming dividend of S$0.027 per share at 3.0% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Alternate Director recently bought S$132k worth of stock

Full year 2022 earnings: EPS and revenues exceed analyst expectations

First Sponsor Group Limited Proposes Final Dividend for the Financial Year Ended 31 December 2022 Paid on or Around 19 May 2023

Insufficient new directors

Price target decreased to S$1.39

Insufficient new directors

Insufficient new directors

First Sponsor Group Limited Appoints Mr. Frans Van Toor as Chief Executive Officer (European Office & Residential Operations)

First Sponsor Group Limited Announces Change of Singapore Business Office Address

Price target decreased to S$1.39

Insufficient new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

First Sponsor Group Limited, Annual General Meeting, Apr 26, 2022

Insufficient new directors

Upcoming dividend of S$0.024 per share

Consensus forecasts updated

Group CEO & Executive Director exercised options to buy S$4.2m worth of stock.

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

First Sponsor Group Limited Announces Second Interim Tax-Exempt (One-Tier) Dividend for the Financial Year Ended 31 December 2021, Payable on or About 1 April 2022

Upcoming dividend of S$0.011 per share

Alternate Director exercised options to buy S$932k worth of stock.

Non-Executive Chairman recently bought S$879k worth of stock

Consensus EPS estimates increase to S$0.11

These 4 Measures Indicate That First Sponsor Group (SGX:ADN) Is Using Debt Extensively

One First Sponsor Group Limited (SGX:ADN) Analyst Is Reducing Their Forecasts For This Year

Full year 2020 earnings released: EPS S$0.12 (vs S$0.22 in FY 2019)

New 90-day high: S$1.39

Non-Executive Chairman recently bought S$274k worth of stock

First Sponsor Group Limited (SGX:ADN) entered into a conditional sale and purchase agreement to acquire Guangzhou Panyu Chuang's Real Estate Development Company Limited from Chuang's China Realty Limited for CNY 1.6 billion.

Full year 2020 earnings released: EPS S$0.12 (vs S$0.22 in FY 2019)

Revenue and earnings miss expectations

Upcoming Dividend of S$0.02 Per Share

New 90-day high: S$1.36

First Sponsor Group (SGX:ADN) Takes On Some Risk With Its Use Of Debt

Update: First Sponsor Group (SGX:ADN) Stock Gained 14% In The Last Five Years

First Sponsor Group (SGX:ADN) Is Growing Earnings But Are They A Good Guide?

Analysts lower revenue estimates to S$255.3m

Third quarter earnings released

New 90-day high - S$1.32

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance